Literature DB >> 32037659

Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium-glucose cotransporter 2 inhibitors.

Milton Packer1,2.   

Abstract

In five large-scale trials involving >40 000 patients, sodium-glucose cotransporter 2 (SGLT2) inhibitors decreased the risk of serious heart failure events by 25-40%. This effect cannot be explained by control of hyperglycaemia, since it is not observed with antidiabetic drugs with greater glucose-lowering effects. It cannot be attributed to ketogenesis, since it is not causally linked to ketone body production, and the benefit is not enhanced in patients with diabetes. The effect cannot be ascribed to a natriuretic action, since SGLT2 inhibitors decrease natriuretic peptides only modestly, and they reduce cardiovascular death, a benefit that diuretics do not possess. Although SGLT2 inhibitors increase red blood cell mass, enhanced erythropoiesis does not favourably influence the course of heart failure. By contrast, experimental studies suggest that SGLT2 inhibitors may reduce intracellular sodium, thereby preventing oxidative stress and cardiomyocyte death. Additionally, SGLT2 inhibitors induce a transcriptional paradigm that mimics nutrient and oxygen deprivation, which includes activation of adenosine monophosphate-activated protein kinase, sirtuin-1, and/or hypoxia-inducible factors-1α/2α. The interplay of these mediators stimulates autophagy, a lysosomally-mediated degradative pathway that maintains cellular homeostasis. Autophagy-mediated clearance of damaged organelles reduces inflammasome activation, thus mitigating cardiomyocyte dysfunction and coronary microvascular injury. Interestingly, the action of hypoxia-inducible factors-1α/2α to both stimulate erythropoietin and induce autophagy may explain why erythrocytosis is strongly correlated with the reduction in heart failure events. Therefore, the benefits of SGLT2 inhibitors on heart failure may be mediated by a direct cardioprotective action related to modulation of pathways responsible for cardiomyocyte homeostasis.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Entities:  

Keywords:  Autophagy; Sodium-glucose cotransporter 2 inhibitors; Sodium-hydrogen exchanger

Mesh:

Substances:

Year:  2020        PMID: 32037659     DOI: 10.1002/ejhf.1732

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  22 in total

Review 1.  Glucose-Lowering Medications and Cardiovascular Outcomes.

Authors:  Madhan Shanmugasundaram; J R Exequiel Pineda; Sangeetha Murugapandian
Journal:  Curr Cardiol Rep       Date:  2021-03-02       Impact factor: 2.931

Review 2.  Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling.

Authors:  Husam M Salah; Subodh Verma; Carlos G Santos-Gallego; Ankeet S Bhatt; Muthiah Vaduganathan; Muhammad Shahzeb Khan; Renato D Lopes; Subhi J Al'Aref; Darren K McGuire; Marat Fudim
Journal:  J Cardiovasc Transl Res       Date:  2022-03-15       Impact factor: 4.132

3.  Enhanced Expression and Function of Renal SGLT2 (Sodium-Glucose Cotransporter 2) in Heart Failure: Role of Renal Nerves.

Authors:  Kenichi Katsurada; Shyam S Nandi; Neeru M Sharma; Kaushik P Patel
Journal:  Circ Heart Fail       Date:  2021-11-18       Impact factor: 8.790

Review 4.  Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease.

Authors:  Tian Gan; Yi Song; Feng Guo; Guijun Qin
Journal:  Mol Biol Rep       Date:  2022-08-24       Impact factor: 2.742

Review 5.  β-Hydroxybutyrate in Cardiovascular Diseases : A Minor Metabolite of Great Expectations.

Authors:  Shao Wei; Liu Binbin; Wu Yuan; Zhang Zhong; Lin Donghai; Huang Caihua
Journal:  Front Mol Biosci       Date:  2022-06-13

Review 6.  Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications.

Authors:  Jun Ren; Ne N Wu; Shuyi Wang; James R Sowers; Yingmei Zhang
Journal:  Physiol Rev       Date:  2021-05-05       Impact factor: 37.312

7.  Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care.

Authors:  Milton Packer
Journal:  Eur Heart J       Date:  2020-07-01       Impact factor: 29.983

Review 8.  COVID-19 and the Heart and Vasculature: Novel Approaches to Reduce Virus-Induced Inflammation in Patients With Cardiovascular Disease.

Authors:  Bernard S Kadosh; Michael S Garshick; Juan Gaztanaga; Kathryn J Moore; Jonathan D Newman; Michael Pillinger; Ravichandran Ramasamy; Harmony R Reynolds; Binita Shah; Judith Hochman; Glenn I Fishman; Stuart D Katz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-07-20       Impact factor: 8.311

Review 9.  Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects.

Authors:  Giuseppe Palmiero; Arturo Cesaro; Erica Vetrano; Pia Clara Pafundi; Raffaele Galiero; Alfredo Caturano; Elisabetta Moscarella; Felice Gragnano; Teresa Salvatore; Luca Rinaldi; Paolo Calabrò; Ferdinando Carlo Sasso
Journal:  Int J Mol Sci       Date:  2021-05-30       Impact factor: 5.923

Review 10.  SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy.

Authors:  Na Li; Hong Zhou
Journal:  Drug Des Devel Ther       Date:  2020-11-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.